Sugi Predict

Sugi Predict / Compounds / SCHEMBL9945484

SCHEMBL9945484

SCHEMBL9945484

C=CC(=O)Nc1cccc(Oc2nc(Cl)ncc2Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 11/20 0.67
▸ BTK Q06187 6/20 0.64
▸ JAK2 O60674 2/20 0.61
▸ BLK P51451 2/20 0.61
▸ BMX P51813 2/20 0.61
▸ JAK3 P52333 2/20 0.61
▸ CTSC P53634 4/20 0.58
▸ ITK Q08881 3/20 0.58
▸ PLK4 O00444 1/20 0.55
▸ GAK O14976 1/20 0.55
▸ NUAK1 O60285 1/20 0.55
▸ FLT3 P36888 1/20 0.55
▸ PTK2 Q05397 1/20 0.55
▸ ERBB4 Q15303 1/20 0.55
▸ DCLK3 Q9C098 1/20 0.55
▸ NUAK2 Q9H093 1/20 0.55
▸ EML4 Q9HC35 1/20 0.55
▸ EIF2AK4 Q9P2K8 1/20 0.55
▸ ALK Q9UM73 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29534445 1.00 EGFR (0.67) EGFRBTKJAK2BLKBMX
SCHEMBL9945482 0.89 EGFR (0.57) EGFRBTKJAK2BLKBMX
SCHEMBL9946942 0.89 EGFR (0.67) EGFRBTKJAK2BLKBMX
SCHEMBL9945479 0.89 BTK (0.65) EGFRBTKJAK2BLKBMX
SCHEMBL16370708 0.89 EGFR (0.73) EGFRBTKCTSCITK
SCHEMBL16391074 0.87 EGFR (0.65) EGFRBTKJAK2BLKBMX
SCHEMBL9946937 0.86 EGFR (0.66) EGFRBTKITK
SCHEMBL21358332 0.83 EGFR (0.59) EGFRBTKJAK2BLKBMX
SCHEMBL23899138 0.81 MAP2K7 (0.59) EGFRBTKCTSCITK
SCHEMBL9924751 0.81 EGFR (0.72) EGFRBTKJAK2BLKBMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218704-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2022-07-14 — — US disclosed
US-20200276194-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2020-09-03 — — US disclosed
US-10434101-B2 Heterocyclic compounds and uses thereof CELGENE CAR LLC (BM) 2019-10-08 — — US disclosed
US-9867824-B2 Heterocyclic compounds and uses thereof CELGENE CAR LLC (BM) 2018-01-16 — — US disclosed
US-9868723-B2 Mutant-selective EGFR inhibitors and uses thereof CELGENE CAR LLC (BM) 2018-01-16 — — US disclosed
US-9868723-B2 Mutant-selective EGFR inhibitors and uses thereof CELGENE CAR LLC (BM) 2018-01-16 — — US disclosed
US-9867824-B2 Heterocyclic compounds and uses thereof CELGENE CAR LLC (BM) 2018-01-16 — — US disclosed
US-20170027937-A1 Heterocyclic Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY 2017-02-02 — — US disclosed
US-20170027937-A1 Heterocyclic Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY 2017-02-02 — — US disclosed
US-20160332994-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-11-17 — — US disclosed
US-8975249-B2 Heterocyclic compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-03-10 — — US disclosed
US-8975249-B2 Heterocyclic compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-03-10 — — US disclosed
US-20150025055-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 — — US disclosed
US-20150025055-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 — — US disclosed
US-8796255-B2 Mutant-selective EGFR inhibitors and uses thereof Celgene Avilomics Research, Inc (US) 2014-08-05 — — US disclosed
US-8796255-B2 Mutant-selective EGFR inhibitors and uses thereof Celgene Avilomics Research, Inc (US) 2014-08-05 — — US disclosed
US-20120157426-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-21 — — US disclosed
US-20120157426-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-21 — — US disclosed
US-20120149687-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-14 — — US disclosed
US-20120149687-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332994-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF EGFR, ERBB3, ERBB2 EGFR 1/4885BTK 46/4885JAK2 42/4885
US-10434101-B2 Heterocyclic compounds and uses thereof ABCG2, CYP3A5, CYP3A43 EGFR 2849/4885BTK 988/4885JAK2 183/4885
US-20170027937-A1 Heterocyclic Compounds and Uses Thereof ABCG2, CYP3A5, CYP3A43 EGFR 2849/4885BTK 988/4885JAK2 183/4885
US-20220218704-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 EGFR 2849/4885BTK 988/4885JAK2 183/4885
US-20200276194-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 EGFR 2849/4885BTK 988/4885JAK2 183/4885
US-20120149687-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 EGFR 2849/4885BTK 988/4885JAK2 183/4885
US-20150025055-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF EGFR, ERBB3, ERBB2 EGFR 1/4885BTK 46/4885JAK2 42/4885
US-20120157426-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF EGFR, ERBB3, ERBB2 EGFR 1/4885BTK 46/4885JAK2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.